Rupee depreciation to hit SmithKline, Pfizer - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Rupee depreciation to hit SmithKline, Pfizer

Jun 13, 2000

The recent depreciation of the rupee is likely to hit mutinational pharmaceutical companies such as SmithKline Beecham and Pfizer quite adversely. This is primarily because imports not only account for a relatively larger proportion of their raw material cost but these companies also import a substantial amount (in terms of their raw material imports) of finished goods. (SmithKline actually imports its Hepatitis–B formulation Engerix from the Belgium plant of its parent.)

  Imports (Rs m)
Company Raw Material Finished goods
SmithKline Pharma 75.1 679.7
Pfizer 93.1 99.1

While the Indian companies such as Ranbaxy, Cipla and Dr Reddys should be net gainers of the rupee depreciation since their exports account for a decent proportion of their turnover, the fact remains that unless their exports account for value added formulations the foreign buyers usually insist on proportionate discounts (proportionate to the value of depreciation). The net impact would however be positive for these companies.

Company Exports
(Rs m)
Imports
(Rs m)
Exports / Sales Imports of
Raw Material
Ranbaxy 8,138.1 3,138.2 48.8% 48.4%
Dr Reddys 1,184.2 761.2 27.8% 46.0%
Cipla 1,163.5 5,520.4 18.9% 30.0%
Glaxo 761.9 683.4 8.6% 12.2%
SmithKline Beecham 190.6 760.5 5.9% 24.0%
Pfizer 67.0 201.8 2.0% 10.8%
German Remedies 59.0 11.9 9.8% 31.6%

There are also companies such as Glaxo and German Remedies, which import certain bulk drugs from their parents but they also serve as a sourcing base for the supply of older formulations to their parents. For instance Glaxo imports cefutoxamine (the bulk drug for Ceftum) from its parent but also supplies ranitidine to its parent. For these companies while the overall impact of the depreciation of the rupee would be negative it would be alleviated to some extent due to their exports.


Equitymaster requests your view! Post a comment on "Rupee depreciation to hit SmithKline, Pfizer". Click here!

  

More Views on News

ADVANCED ENZYME TECHNOLOGIES Share Price Up by 5%; BSE HEALTHCARE Index Up 1.0% (Market Updates)

Sep 30, 2020 | Updated on Sep 30, 2020

ADVANCED ENZYME TECHNOLOGIES share price is trading up by 5% and its current market price is Rs 309. The BSE HEALTHCARE is up by 1.0%. The top gainers in the BSE HEALTHCARE Index is ADVANCED ENZYME TECHNOLOGIES (up 5.0%). The top losers are ERIS LIFESCIENCES LIMITED (down 0.1%) and FORTIS HEALTHCARE (down 0.1%).

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Sep 30, 2020 02:35 PM

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS